MAPK3 and familial pancreatic carcinoma: It is annotated as the Regulatory Class ‘Impairing’, indicating that upregulation of ERK1 phosphorylation at Thr202 reduces the therapeutic efficacy of CUDC–907 in pancreatic cancer.